article thumbnail

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

MedCity News

The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.

article thumbnail

Fierce Pharma Asia—Pfizer's eye for China ADC deals; Astellas' gastric cancer rejection

Fierce Pharma

. | Pfizer mused on ADC opportunities in China, while Takeda's R&D head revealed details behind the company's competitive TYK2 deal with Nimbus at this year's J.P. Astellas received a manufacturing-related rejection for its gastric cancer candidate. Morgan Healthcare Conference. And more.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.

article thumbnail

The competitive edge: Unlocking the full potential of autoinjectors through comprehensive in-house manufacturing

Pharmaceutical Technology

To optimise autoinjector combination product development, it is crucial for pharma and biotech to partner with device companies that have in-house control over the whole device manufacturing process.

article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.

article thumbnail

FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing, manufacturing concerns

Fierce Pharma

With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely.